Oncology

HR+ HER2- Breast Cancer

Advertisment
HR+ HER2- Breast Cancer and the Problem of Resistance to Endocrine Therapies
HR+ HER2- Breast Cancer

HR+ HER2- Breast Cancer and the Problem of Resistance to Endocrine Therapies

expert roundtables
By Susan Dent, MD; Matthew P. Goetz, MD; Joseph A. Sparano, MD, FACP
Extending Overall Survival in HR+/HER2- Advanced Breast Cancer
HR+ HER2- Breast Cancer

Extending Overall Survival in HR+/HER2- Advanced Breast Cancer

expert roundtables
By Susan Dent, MD; Matthew P. Goetz, MD; Joseph A. Sparano, MD, FACP
HR+ HER2- Breast Cancer: Approach to Metastatic Disease
HR+ HER2- Breast Cancer

HR+ HER2- Breast Cancer: Approach to Metastatic Disease

expert roundtables
By Susan Dent, MD; Matthew P. Goetz, MD; Joseph A. Sparano, MD, FACP
Preserving Health-Related Quality of Life in Patients With Advanced Breast Cancer
HR+ HER2- Breast Cancer

Preserving Health-Related Quality of Life in Patients With Advanced Breast Cancer

expert roundtables
By Joseph A. Sparano, MD, FACP; Matthew P. Goetz, MD; Susan Dent, MD
The Role of Biomarkers in Treatment Selection for Patients With HR+ HER2- Metastatic Breast Cancer
HR+ HER2- Breast Cancer

The Role of Biomarkers in Treatment Selection for Patients With HR+ HER2- Metastatic Breast Cancer

expert roundtables
By Joseph A. Sparano, MD, FACP; Matthew P. Goetz, MD; Susan Dent, MD
Load More   

Experts in HR+ HER2- Breast Cancer

+1

Meet the Experts   

Advertisment